RimabotulinumtoxinB: An Update.

IF 2.5 3区医学 Q2 DERMATOLOGY

Dermatologic Surgery Pub Date : 2024-09-01 Epub Date: 2024-07-01 DOI:10.1097/DSS.0000000000004253

Teresa Song, Ellen S Marmur

{"title":"RimabotulinumtoxinB: An Update.","authors":"Teresa Song, Ellen S Marmur","doi":"10.1097/DSS.0000000000004253","DOIUrl":null,"url":null,"abstract":"Background: Botulinum type-A toxin is a well established aesthetic and medical treatment. While the usage of type-B toxin is less common, there is a growing interest in using type-B toxin, especially in those who are treatment resistant.Objective: To evaluate the primary FDA-approved clinical applications of rimabotulinumtoxinB, along with established and emerging off-label clinical indications.Material and methods: Articles were reviewed from PubMed database and Food and Drug Adminstration guidelines.Results: Facial rhytids tend to use a higher conversion ratio between type A and type B toxin, due to type B toxin's weaker affinity to muscles and higher affinity for sweat glands. Specially, a 1:100 to 1:50 ratio was utilized for glabellar rhytids, a 1:25 to 1:50 ratio for periocular rhytids, a 1:50 to 1:66.6 ratio for cervical dystonia, a 1:20 to 1:50 ratio for hyperhidrosis, and a 1:25 to 30 ratio for sialorrhea.Conclusion: Type B toxin has demonstrated its safety and efficacy in treating facial rhytids, cervical dystonia, sialorrhea and hyperhidrosis, with potential for novel applications under investigation. Regardless of injection location and clinical applications, dry mouth and dysphagia remained the most common side effects. Across all indications, type B toxin appeared to have a faster onset of action, a dose-dependent clinical duration, and a dose-dependent adverse effect profile.","PeriodicalId":11289,"journal":{"name":"Dermatologic Surgery","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatologic Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/DSS.0000000000004253","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/1 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Botulinum type-A toxin is a well established aesthetic and medical treatment. While the usage of type-B toxin is less common, there is a growing interest in using type-B toxin, especially in those who are treatment resistant.

Objective: To evaluate the primary FDA-approved clinical applications of rimabotulinumtoxinB, along with established and emerging off-label clinical indications.

Material and methods: Articles were reviewed from PubMed database and Food and Drug Adminstration guidelines.

Results: Facial rhytids tend to use a higher conversion ratio between type A and type B toxin, due to type B toxin's weaker affinity to muscles and higher affinity for sweat glands. Specially, a 1:100 to 1:50 ratio was utilized for glabellar rhytids, a 1:25 to 1:50 ratio for periocular rhytids, a 1:50 to 1:66.6 ratio for cervical dystonia, a 1:20 to 1:50 ratio for hyperhidrosis, and a 1:25 to 30 ratio for sialorrhea.

Conclusion: Type B toxin has demonstrated its safety and efficacy in treating facial rhytids, cervical dystonia, sialorrhea and hyperhidrosis, with potential for novel applications under investigation. Regardless of injection location and clinical applications, dry mouth and dysphagia remained the most common side effects. Across all indications, type B toxin appeared to have a faster onset of action, a dose-dependent clinical duration, and a dose-dependent adverse effect profile.

查看原文本刊更多论文

利马菌素 B：最新进展。

背景：A 型肉毒杆菌毒素是一种成熟的美容和医疗方法。虽然 B 型肉毒杆菌毒素的使用并不常见，但人们对使用 B 型肉毒杆菌毒素的兴趣却日益浓厚，尤其是那些对治疗有抗药性的患者：评估 FDA 批准的 B 型利马菌素的主要临床应用，以及已确立和新出现的标签外临床适应症：从 PubMed 数据库和食品药品管理局指南中查阅相关文章：结果：由于 B 型毒素对肌肉的亲和力较弱，而对汗腺的亲和力较强，因此面部除皱往往使用 A 型和 B 型毒素之间较高的转换率。具体而言，眼睑皱纹的转换比例为 1:100-1:50，眼周皱纹的转换比例为 1:25-1:50，颈肌张力障碍的转换比例为 1:50-1:66.6，多汗症的转换比例为 1:20-1:50，霰粒肿的转换比例为 1:25-30：结论：B型毒素在治疗面部皱纹、颈肌张力障碍、睑下垂和多汗症方面的安全性和有效性已得到证实，其新的应用潜力正在研究中。无论注射位置和临床应用如何，口干和吞咽困难仍然是最常见的副作用。在所有适应症中，B 型毒素似乎起效更快，临床持续时间与剂量有关，不良反应与剂量有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Dermatologic Surgery 医学-皮肤病学

CiteScore

3.10

自引率

16.70%

发文量

547

期刊介绍： Exclusively devoted to dermatologic surgery, the Dermatologic Surgery journal publishes the most clinically comprehensive and up-to-date information in its field. This unique monthly journal provides today’s most expansive and in-depth coverage of cosmetic and reconstructive skin surgery and skin cancer through peer-reviewed original articles, extensive illustrations, case reports, ongoing features, literature reviews and correspondence. The journal provides information on the latest scientific information for all types of dermatologic surgery including: -Ambulatory phlebectomy- Blepharoplasty- Body contouring- Chemical peels- Cryosurgery- Curettage and desiccation- Dermabrasion- Excision and closure- Flap Surgery- Grafting- Hair restoration surgery- Injectable neuromodulators- Laser surgery- Liposuction- Microdermabrasion- Microlipoinjection- Micropigmentation- Mohs micrographic surgery- Nail surgery- Phlebology- Sclerotherapy- Skin cancer surgery- Skin resurfacing- Soft-tissue fillers. Dermatologists, dermatologic surgeons, plastic surgeons, oculoplastic surgeons and facial plastic surgeons consider this a must-read publication for anyone in the field.

文献相关原料

公司名称	产品信息	采购帮参考价格